Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker 'OTC BB: TYNP'

Tuesday, March 11, 2008 General News J E 4
CHENGDU, China, March 11 Viscorp Inc.(OTC Bulletin Board: VSCO; TYNP), a manufacturer and supplier of modernizedtraditional Chinese medicine ("TCM") based in Chengdu, China, today announcedthat it has changed its name to Tianyin Pharmaceutical, Co., Inc. Thecorporate name change is effective immediately.

In addition, effective March 11, 2008, the Company will trade under a newsymbol TYNP with the new CUSIP Number of 88630M 104.

Viscorp and Raygere Ltd, which conducts its business through ChengduTianyin Pharmaceutical Co., LTD. ("Tianyin"), jointly announced on January 16,2008, that the companies completed a Definitive Share Exchange Agreementwhereby Viscorp acquired all of the outstanding and issued shares of Tianyin.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 34 modernized TCMs in the market, 22 of which are listed in thehighly selective National Medicine Catalog of the National Medical InsuranceProgram. Tianyin owns and operates two GMP manufacturing facilities and anR&D platform supported by leading Chinese academic institutions. The Companyhas a pipeline of 51 pharmaceutical products pending approval. Tianyin has anextensive nationwide distribution network throughout China with a sales forceof 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Provincewith two manufacturing facilities and a total of 869 employees. Tianyinachieved revenue of $20.4 million and net income of $3.95 million in FY2007ending June 30, 2007.

Safe Harbor Statement

The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO Tel: +86-158-2122-5642 Email: Investors: HC International Alan Sheinwald Tel: +1-914-669-0222 Email:

SOURCE Tianyin Pharmaceutical, Co., Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Birner Dental Management Services, Inc. Schedules ...
InforMedix Retains Murdock Capital Partners